UB Paderborn / Katalog / Suche / in CDI

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2215-2222

2011

Volltextzugriff (PDF)

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

Cancer research (Chicago, Ill.), 2009-04, Vol.69 (7), p.3021-3031

2009

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas

Clinical cancer research, 2006-12, Vol.12 (24), p.7261-7270

2006

Volltextzugriff (PDF)

EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation

The Journal of biological chemistry, 2010-06, Vol.285 (24), p.18575-18585

2010

Volltextzugriff (PDF)

The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target

PloS one, 2013-07, Vol.8 (7), p.e67668

2013

Volltextzugriff (PDF)

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2021-08, Vol.22 (8), p.1126-1138

2021

Volltextzugriff (PDF)

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia

European journal of haematology, 2005-02, Vol.74 (2), p.117-120

2005

Volltextzugriff (PDF)

C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes

Cancer biology & therapy, 2008-06, Vol.7 (6), p.856-863

2008

Volltextzugriff (PDF)

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Journal of clinical oncology, 2017-01, Vol.35 (3), p.352-360

2017

Volltextzugriff (PDF)

A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

Clinical cancer research, 2022-03, Vol.28 (5), p.882-892

2022

Volltextzugriff (PDF)

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer

Thyroid (New York, N.Y.), 2022-05, Vol.32 (5), p.515

2022

Volltextzugriff (PDF)

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.6001-6001

2021

Volltextzugriff (PDF)

MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS1142-TPS1142

2013

Volltextzugriff (PDF)

Abstract A055: RSPO3 overexpression is a characteristic feature of signet ring gastrointestinal malignancies

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A055-A055

2018

Volltextzugriff (PDF)

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription

Laboratory investigation, 2009-03, Vol.89 (3), p.301-314

2009

Volltextzugriff (PDF)

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

Journal of thoracic oncology, 2011-01, Vol.6 (1), p.109-114

2011

Volltextzugriff (PDF)

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

Gynecologic oncology, 2008-07, Vol.110 (1), p.49-55

2008

Volltextzugriff (PDF)

Abstract CT322: Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT322-CT322

2014

Volltextzugriff (PDF)

Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1727-1727

2017

Volltextzugriff (PDF)

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

Blood, 2016-12, Vol.128 (22), p.5108-5108

2016

Volltextzugriff (PDF)

Abstract 404: Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.404-404

2016

Volltextzugriff (PDF)

Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C42-C42

2015

Volltextzugriff (PDF)

MET Receptor Tyrosine Kinase

Journal of thoracic oncology, 2009-11, Vol.4 (11), p.S1064-S1065

2009

Volltextzugriff (PDF)

Neurocisticercose: estudo clínico e patológico de 27 casos de necrópsia

Arquivos de neuro-psiquiatria, 2000-09, Vol.58 (3B), p.883-889

2000

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas

EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation

The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target

Paxillin Is a Target for Somatic Mutations in Lung Cancer : Implications for Cell Growth and Invasion

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia

C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial

MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer

Abstract A055: RSPO3 overexpression is a characteristic feature of signet ring gastrointestinal malignancies

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

Abstract CT322: Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)

Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

Abstract 404: Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

MET Receptor Tyrosine Kinase

Neurocisticercose: estudo clínico e patológico de 27 casos de necrópsia

Suchergebnisse filtern